Type of information: Company acquisition
Acquired company: Ignyta (USA - CA)
Acquiring company: Roche (Switzerland)
Amount: $ 1.7 billion
- • On December 21, 2017, Roche and Ignyta announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta at a price of $ 27.00 per share in an all-cash transaction. This corresponds to a total transaction value of $ 1.7 billion on a fully diluted basis. This price represents a premium of 74% to Ignyta’s closing price on 21 December 2017 and a premium of 71% and 89% to Ignyta’s 30-day and 90-day volume weighted average share price on 21 December 2017, respectively. The merger agreement has been unanimously approved by the boards of Ignyta and Roche.
- Under the terms of the merger agreement, Roche will promptly commence a tender offer, to acquire all outstanding shares of Ignyta common stock, and Ignyta will file a recommendation statement containing the unanimous recommendation of the Ignyta board that Ignyta’s shareholders tender their shares to Roche.
Related: Cancer - Oncology